The University Hospital Cologne and Gustave Roussy have launched REDUCE-LUNG, a joint study focused on improving outcomes for lung cancer patients over 70.

A Phase 2 clinical trial reveals that asunercept, a FasL inhibitor, significantly accelerates recovery in patients with severe COVID-19, reducing the average recovery time from 13 to 8 days.

The MATTERHORN trial demonstrated that transcatheter edge-to-edge repair (TEER) is non-inferior to surgery in treating secondary mitral regurgitation (MR) at one year.

Researchers are developing an AI model to classify genetic variants of the ABCA4 gene, crucial for understanding Stargardt disease.

A phase II trial (MOLTO) found that a chemotherapy-free regimen of atezolizumab, venetoclax, and obinutuzumab yielded a 67.9% overall response rate in patients with Richter transformation.

Skanska has secured an additional $66 million contract with the University of Virginia to construct the Paul and Diane Manning Institute of Biotechnology, bringing advanced translational research capabilities to the Commonwealth.

Final results from the phase II GEOMETRY mono-1 trial reinforce capmatinib's effectiveness in treating NSCLC patients with MET exon 14 skipping mutations.

New data from the PROVE study reveals cefiderocol achieves better clinical outcomes when used as empiric (64.6%) or documented therapy (67.4%) compared to salvage therapy (58.2%) in serious gram-negative infections.

The Lancashire Clinical Trials Unit (CTU) has been granted full registration status by the UK Clinical Research Collaboration (UKCRC).

A multi-institutional research team secured a $2.7 million NIH grant to develop patient-specific molds for breast reconstruction after mastectomy, aiming to improve efficiency and psychosocial outcomes.

NIH is funding research to develop precision probiotic interventions that account for human heterogeneity, aiming to improve therapeutic responses.

University of Birmingham researchers are revolutionizing cancer diagnosis through innovative MRI and machine learning techniques that can identify pediatric brain tumor types in just ten minutes.

Vyalev, a new subcutaneous drug therapy by AbbVie for Parkinson's disease, has been approved by the FDA in October 2024 after successful Phase 3 trials.

A clinical trial is underway at the University of Miami Miller School of Medicine, among 15 sites, to assess hyperbaric oxygen therapy (HBOT) for ulcerative colitis treatment.

The University of Colorado Anschutz Medical Campus will receive up to $46 million from ARPA-H to advance vision-restoring human whole eye transplantation.

Canadian researchers at McMaster University have begun phase-2 clinical trials for AeroVax, an innovative inhaled COVID-19 vaccine that directly targets the lungs and upper airways where infection begins.

University of Alberta researchers have developed Zelenirstat, an innovative oral cancer medication that works by preventing cancer cell spread and starving tumors.

Researchers at the University of Montana, in partnership with Inimmune, have advanced a novel cancer treatment into Phase 1 human clinical trials.

Researchers at the University of Pittsburgh have validated a blood test that measures over 100 genetic sequences associated with Alzheimer's disease, potentially replacing spinal taps.

A clinical trial is underway to compare ketamine and fentanyl for prehospital pain management in trauma patients.